
usd jul pm et
summari compani provid medic product servic primarili area orthoped
medic surgic medsurg well neurotechnolog spine
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
apr stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra reiter
corpor lift
target base
multipl ep
multipl peer
driven increasingli strong competit
posit ep vs
higher estim lift ep
ep
sale grew organ
billion organ basi orthopaed
sale grew yoy medsurg
neurotechnolog spine
continu see market share gain knee
replac driven mako robot sale
increas robot util believ
success mako knee procedur
enabl compani achiev share gain
histor stabl hip replac market
mako hip procedur grew doubl digit
total mako procedur grew
approxim year-over-year
approxim led growth
mako knee procedur /kevin huang cfa
oper competit area global
medic devic industri character rapid
technolog innov market share volatil
medical/surg suppli unit may vulner
reduct hospit capit equip spend
demand orthoped product becom
less immun econom cycl
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview corp one world lead medic technolog compani
compani offer innov product servic orthopaed revenu medic
surgic neurotechnolog spine aim improv patient hospit
orthopaed segment consist primarili implant use hip knee joint replac
trauma extrem surgeri goal deliv advanc implant design special
instrument make orthopaed surgeri recoveri simpler faster effect artifici
joint made cobalt chromium titanium alloy ceram ultra-high molecular weight
polyethylen implant patient whose natur joint damag arthriti
osteoporosi diseas injuri also sell trauma-rel product use primarili
fixat fractur result sudden injuri includ intern fixat devic nail plate
screw extern fixat devic pin wire connect bar receiv
clearanc unit state food drug administr fda mako total knee applic
robotic-arm assist technolog complet full commerci launch one four
lead global competitor joint replac trauma extrem product three
inc depuy synth johnson johnson compani smith nephew
medic surgic medsurg segment product includ surgic equip navig
system instrument endoscop commun system endoscopi patient handl
emerg medic equip intens care dispos product medic reprocess
remanufactur medic devic sustain medic devic product use varieti
medic specialti mani competitor medsurg segment launch
next gener set power tool compris sagitt saw reciproc saw rotari drill
neurotechnolog spine product includ neurosurg neurovascular spinal implant devic
neurotechnolog offer includ product use minim invas endovascular techniqu
comprehens line product tradit brain open skull base surgic procedur
orthobiolog biosurgeri product includ synthet bone graft vertebr augment
product minim invas product treatment acut ischem hemorrhag stroke
one five lead global competitor neurotechnolog four johnson
 johnson terumo corpor inc one five lead global competitor spine
four sofamor danek inc subsidiari depuy synth
inc globu medic inc
corpor strategi seek achiev sale growth high-end medic technolog
med-tech industri maintain capit alloc strategi priorit acquisit
dividend share repurchas invest million acquisit paid
million dividend repurchas million share success acquisit
tend small rel market capit
novemb acquir global leader complex spine minim
invas solut billion februari acquir entellu medic medic technolog
compani make product design minim invas treatment variou ear nose throat
diseas state million septemb also acquir novadaq technolog inc
lead develop fluoresc imag million
specif lot product respons warn letter receiv food drug
administr fda resum ship product return full suppli capac end
product manufactur intens care dispos product acquir
financi trend achiev compound annual growth rate compound-annual-growth-rate revenu five
year end includ benefit sever acquisit revenu grew
year-over-year billion typic invest revenu research
develop spent million decemb quarter
moder net debt total capit low leverag debt ebitda ratio
gener posit cash flow oper least past five year billion
given financi posit see near-term difficulti compani pursu
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
bullish sinc june technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
neutral continu expect compani
sub-industri achiev robust organ
growth posit macroeconom environ
compani gener benefit new
product launch laxer food drug
administr fda technolog advanc
sub-industri also mani product area
histor recession-resist
equip use non-elect procedur
howev valuat health care equip
compani elev rel
composit suggest posit
fundament reflect share
think higher valuat
sub-industri mostli warrant
strong recent margin expans revenu
growth associ robust product
expect sub-industri earn rise
high-single-digit percentag driven
continu pipelin innov new product
emerg market expans speed
new product come market
increas recent year
success effort fda reduc
approv time medic devic
time see price pressur incess
headwind medic equip compani
impact china-u trade war appear
insignific far medic
equip compani especi sinc
base medic equip manufactur
sourc insignific amount product
input china addit
chines govern seek lower health
care cost provid better health care
insul medic equip
sub-industri mount trade tension
larg medic equip target
chines tariff mean certain
compani
like
hurt trade tension howev bigger
concern medic equip
manufactur potenti trade
tension caus signific slowdown
possibl threat state american
health care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal although decis could take
coupl year reach democrat
took control hous repres
period think
see substanti effort
republican trump administr
tri repeal
anoth legisl issu could impact
medic equip manufactur
potenti return medic devic tax
medic devic tax suspend
end congress fail
repeal suspend tax medic
devic manufactur could significantli
gener see posit long-term
fundament includ increas global
demand cost-effect value-bas
health care age popul rise
outlay result steadi flow
innov product revenu growth
year-to-d june
vs increas valu
 composit index
vs declin composit
base index
five-year market price perform jul
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra keep buy opinion share corpor
maintain target slightli
peer ep estim ep vs
higher estim rais ep
ep sale increas organ
billion organ basi sale orthopaed segment grew
year-over-year medsurg grew neurotechnolog spine grew
encourag placement mako robot quarter compar
mako total knee procedur vs
think mako robot still signific
room growth although rumor acquir
rumor expect manag top prioriti
capit alloc merger acquisit /kevin huang cfa
strong buy buy day ago unconfirm
report stryker corpor approach
acquisit deni discuss regard potenti
acquisit howev disput approach think
still possibl deal given robust pipelin continu
view pipelin favor mani promis avenu growth
much near-term stock perform may hing success approv
launch lotu edg transcathet aortic valv replac
think success execut next step /kevin huang cfa
analyst research note compani news
et cfra reiter buy opinion share stryker corpor
lift target base
multipl ep multipl peer
sustain above-market organ growth driven
increasingli strong competit posit ep vs
higher estim lift ep
ep sale grew organ billion
organ basi orthopaed sale grew yoy medsurg
neurotechnolog spine continu see market share gain
knee replac driven mako robot sale increas robot util
believ success mako knee procedur enabl
compani achiev share gain histor stabl hip replac
market mako hip procedur grew doubl digit total mako
procedur grew approxim year-over-year approxim
led growth mako knee procedur /kevin huang cfa
et cfra keep buy opinion share stryker corpor
lift target multipl
ep estim multipl high end
rang expect acceler growth due
compani improv competit posit ep vs
higher estim rais ep
lift ep sale increas
organ billion organ sale volum grew off-set
due lower price organ basi sale orthopaed segment grew
year-over-year medsurg neurotechnolog spine
instal mako robot global vs prior-year period
syk manag refer strong healthi order book mako
robot multipl time give us confid mako robot placement
sustain momentum overal result expect maintain
pm et cfra keep buy opinion share stryker corpor
lift target
ep estim multipl high end
three-year rang compani improv competit posit
ep vs higher estim lift
ep initi ep sale increas
organ billion driven primarili higher sale volum
off-set slightli lower price organ basi sale
orthopaed segment grew year-over-year medsurg
neurotechnolog spine report growth neurotechnolog
spine busi driven acquisit novemb
move quickli integr manag aim establish
align organ end mako robot except
strong quarter placement mako robot global
vs placement /kevin huang cfa
et cfra keep buy opinion share corpor
lift target slightli
peer ep estim ep vs
lower estim sale increas billion
primarili higher sale volum off-set slightli lower price
organ basi sale orthopaed segment grew year-over-year
medsurg neurotechnolog spine acquir
billion quarter ad spine portfolio synerg
neurotechnolog orthopaed busi placement
mako robot global season slow quarter vs placement
finish provid upgrad exist account sale
forc focu place mako robot new account also highlight
posit earli clinic data relat mako procedur think earli
strength mako robot suggest long runway growth
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
